A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

Summary

This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• COPD (Chronic Obstructive Pulmonary Disease)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

40 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Windward Bio

Last updated on ClinicalTrials.gov

September 15, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites